SlideShare une entreprise Scribd logo
1  sur  22
The German Plan for Rare Diseases:  A Development in Progress J.-Matthias Graf von der Schulenburg Krakow, 14 May 2010
Three questions ,[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
Three questions ,[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
Why do we need  health service research ? Dimensions of an economic evaluation… © Prof. Dr. J.-M. Graf von der Schulenburg Allocation Efficiency Stabilization Cost stability and continuity of the system Distribution Fair allocation Facts Appraisements
Three questions ,[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg “ Are we actually moving in  a circular course, Olaf?”
[object Object],© Prof. Dr. J.-M. Graf von der  Schulenburg
How do we proceed? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
Which  perspectives  were taken into account? © Prof. Dr. J.-M. Graf von der Schulenburg Patient organizations (people concerned)  Evaluation of experiences Health care provider (physicians, industry) Evaluation of markets and science Public organizations/ benefactors Evaluation of structures
Rare Diseases are currently attracting insufficient  attention  in Germany © Prof. Dr. J.-M. Graf von der Schulenburg Quelle : BMG-study  2009
Which individual  care factors  are important for patients? © Prof. Dr. J.-M. Graf von der Schulenburg Source:  BMG-study 2009 High competence of medical care Information about new treatment possibilities Psychosocial care … Fast access to new drugs Europe-wide treatment options Close to residential care
Patients with Rare Diseases need a  comprehensive  and  specialised care ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
[object Object],Rare Diseases from  health care providers  point of view: © Prof. Dr. J.-M. Graf von der Schulenburg Costs of ambulatory treatment for Mucoviscidosis Source: Mucoviscidosis-study 2007 0 – 7 years 8 – 13 years 14 – 17 years 18 – 24 years 25 – 34 years 35 Jahre and older 300 400 500 600 100 200 Reimbursement Other costs Physiotherapy, diet guidance Diagnostic service Laboratory checkup Routine checkup Additional costs of the  institute
Three questions ,[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
Recommendations of the study ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
Aims  of NAMSE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Organisation © Prof. Dr. J.-M. Graf von der Schulenburg
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Organisation © Prof. Dr. J.-M. Graf von der Schulenburg
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Organisation © Prof. Dr. J.-M. Graf von der Schulenburg
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Spheres of activity © Prof. Dr. J.-M. Graf von der Schulenburg
Timetable ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],© Prof. Dr. J.-M. Graf von der Schulenburg
Thank you for your attention!

Contenu connexe

Tendances

Tendances (16)

Olle Larkö at Healthy Britain
Olle Larkö at Healthy BritainOlle Larkö at Healthy Britain
Olle Larkö at Healthy Britain
 
Information is key: how to reach and teach the incontinent patient
Information is key: how to reach and teach the incontinent patientInformation is key: how to reach and teach the incontinent patient
Information is key: how to reach and teach the incontinent patient
 
Human‐machine Coexistence in Groups
Human‐machine Coexistence in GroupsHuman‐machine Coexistence in Groups
Human‐machine Coexistence in Groups
 
How to qualify for a dentist in Finland
How to qualify for a dentist in FinlandHow to qualify for a dentist in Finland
How to qualify for a dentist in Finland
 
Grindlay2008
Grindlay2008Grindlay2008
Grindlay2008
 
The Sahlgrenska academy at UGOT
The Sahlgrenska academy at UGOTThe Sahlgrenska academy at UGOT
The Sahlgrenska academy at UGOT
 
EPRD16 - Pamela Mazzocato - How does lean work in emergency care
EPRD16 - Pamela Mazzocato - How does lean work in emergency careEPRD16 - Pamela Mazzocato - How does lean work in emergency care
EPRD16 - Pamela Mazzocato - How does lean work in emergency care
 
1410 susan pbl_clinical
1410 susan pbl_clinical1410 susan pbl_clinical
1410 susan pbl_clinical
 
Medicine and beyond
Medicine and beyondMedicine and beyond
Medicine and beyond
 
Roberts2009
Roberts2009Roberts2009
Roberts2009
 
Professional impact of clinical research
Professional impact of clinical researchProfessional impact of clinical research
Professional impact of clinical research
 
Moving into Nursing
Moving into NursingMoving into Nursing
Moving into Nursing
 
PMED Opening Workshop - Opening Workshop Remarks - Marie Davidian & Peter Muc...
PMED Opening Workshop - Opening Workshop Remarks - Marie Davidian & Peter Muc...PMED Opening Workshop - Opening Workshop Remarks - Marie Davidian & Peter Muc...
PMED Opening Workshop - Opening Workshop Remarks - Marie Davidian & Peter Muc...
 
The Knowledge Egg Stanford
The Knowledge Egg StanfordThe Knowledge Egg Stanford
The Knowledge Egg Stanford
 
Clinical science 2011
Clinical science 2011Clinical science 2011
Clinical science 2011
 
AAP 2014 PEMCRC Presentation
AAP 2014 PEMCRC PresentationAAP 2014 PEMCRC Presentation
AAP 2014 PEMCRC Presentation
 

En vedette

Il grande ripasso
Il grande ripassoIl grande ripasso
Il grande ripassoguestec990c
 
Anorexia Nervosa By Kevin Feng
Anorexia Nervosa By Kevin FengAnorexia Nervosa By Kevin Feng
Anorexia Nervosa By Kevin FengKDawg
 
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...EURORDIS - Rare Diseases Europe
 
Picturess By KFengggg
Picturess By KFenggggPicturess By KFengggg
Picturess By KFenggggKDawg
 
Research 2008
Research 2008Research 2008
Research 2008achu1010
 
Picturess
PicturessPicturess
PicturessKDawg
 
Directors&Boards Magazine Cover story Q2 2014
Directors&Boards Magazine Cover story Q2 2014Directors&Boards Magazine Cover story Q2 2014
Directors&Boards Magazine Cover story Q2 2014Prista Corporation
 

En vedette (20)

Session 25 steffen_suchert
Session 25 steffen_suchertSession 25 steffen_suchert
Session 25 steffen_suchert
 
D&B Qualities Article Q3 2015
D&B Qualities Article Q3 2015D&B Qualities Article Q3 2015
D&B Qualities Article Q3 2015
 
D&B Questions article Q2 2014
D&B Questions article Q2 2014D&B Questions article Q2 2014
D&B Questions article Q2 2014
 
Pratter Pitch customer 022916
Pratter Pitch customer 022916Pratter Pitch customer 022916
Pratter Pitch customer 022916
 
Session 8 dallapiccola
Session 8 dallapiccolaSession 8 dallapiccola
Session 8 dallapiccola
 
Session 13 francesc_palau
Session 13 francesc_palauSession 13 francesc_palau
Session 13 francesc_palau
 
Workshop 3 - "Presentation of the Epi-Rare project"
Workshop 3 - "Presentation of the Epi-Rare project"Workshop 3 - "Presentation of the Epi-Rare project"
Workshop 3 - "Presentation of the Epi-Rare project"
 
Il grande ripasso
Il grande ripassoIl grande ripasso
Il grande ripasso
 
Anorexia Nervosa By Kevin Feng
Anorexia Nervosa By Kevin FengAnorexia Nervosa By Kevin Feng
Anorexia Nervosa By Kevin Feng
 
Workshop 7 - "Folic acid prevents neural tubes defect"
Workshop 7 - "Folic acid prevents neural tubes defect"Workshop 7 - "Folic acid prevents neural tubes defect"
Workshop 7 - "Folic acid prevents neural tubes defect"
 
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
 
Session 3 le henanff
Session 3 le henanffSession 3 le henanff
Session 3 le henanff
 
Welcome screen session02
Welcome screen session02Welcome screen session02
Welcome screen session02
 
Picturess By KFengggg
Picturess By KFenggggPicturess By KFengggg
Picturess By KFengggg
 
Research 2008
Research 2008Research 2008
Research 2008
 
Session 2 terkel_andersen
Session 2 terkel_andersenSession 2 terkel_andersen
Session 2 terkel_andersen
 
Sesion 2 terkel 14 05 2010 (final)
Sesion 2 terkel 14 05 2010 (final)Sesion 2 terkel 14 05 2010 (final)
Sesion 2 terkel 14 05 2010 (final)
 
Picturess
PicturessPicturess
Picturess
 
Directors&Boards Magazine Cover story Q2 2014
Directors&Boards Magazine Cover story Q2 2014Directors&Boards Magazine Cover story Q2 2014
Directors&Boards Magazine Cover story Q2 2014
 
Session 17 pohla_gubo
Session 17 pohla_guboSession 17 pohla_gubo
Session 17 pohla_gubo
 

Similaire à Session 2 graf_von_der_schulenburg

EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
 
EuroBioForum 2013 - Day 1 | Karin Effertz
 EuroBioForum 2013 - Day 1 | Karin Effertz EuroBioForum 2013 - Day 1 | Karin Effertz
EuroBioForum 2013 - Day 1 | Karin EffertzEuroBioForum
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
Vortrag serbian med_diaspora_2011 12
Vortrag serbian med_diaspora_2011 12Vortrag serbian med_diaspora_2011 12
Vortrag serbian med_diaspora_2011 12LKSedukacija
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
 
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013EUPATI
 
Partnering with Patients: Designing, Participating in and Reporting Health Ou...
Partnering with Patients: Designing, Participating in and Reporting Health Ou...Partnering with Patients: Designing, Participating in and Reporting Health Ou...
Partnering with Patients: Designing, Participating in and Reporting Health Ou...patvocates
 
EUPATI’s framework on Informing the “health-interested” public about medicine...
EUPATI’s framework on Informing the “health-interested” public about medicine...EUPATI’s framework on Informing the “health-interested” public about medicine...
EUPATI’s framework on Informing the “health-interested” public about medicine...Nowgen
 
2010 11 13 european cme forum jan geissler 1.5
2010 11 13 european cme forum jan geissler 1.52010 11 13 european cme forum jan geissler 1.5
2010 11 13 european cme forum jan geissler 1.5jangeissler
 
The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...jangeissler
 
Time matters-brochure-digital
Time matters-brochure-digitalTime matters-brochure-digital
Time matters-brochure-digitalKlaus Schmierer
 
Introduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI updateIntroduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI updateEUPATI
 
Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...Nowgen
 
ENCA 2016 - Genoa - Bas Vastert
ENCA 2016 - Genoa - Bas VastertENCA 2016 - Genoa - Bas Vastert
ENCA 2016 - Genoa - Bas Vastertanton gruss
 
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...jangeissler
 
European Union Action in the field of Rare Diseases
European Union Action in the field of Rare DiseasesEuropean Union Action in the field of Rare Diseases
European Union Action in the field of Rare DiseasesPlan de Calidad para el SNS
 
Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015 Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015 MedicReS
 
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"EURORDIS - Rare Diseases Europe
 

Similaire à Session 2 graf_von_der_schulenburg (20)

EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
 
EuroBioForum 2013 - Day 1 | Karin Effertz
 EuroBioForum 2013 - Day 1 | Karin Effertz EuroBioForum 2013 - Day 1 | Karin Effertz
EuroBioForum 2013 - Day 1 | Karin Effertz
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
Vortrag serbian med_diaspora_2011 12
Vortrag serbian med_diaspora_2011 12Vortrag serbian med_diaspora_2011 12
Vortrag serbian med_diaspora_2011 12
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
 
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
 
Partnering with Patients: Designing, Participating in and Reporting Health Ou...
Partnering with Patients: Designing, Participating in and Reporting Health Ou...Partnering with Patients: Designing, Participating in and Reporting Health Ou...
Partnering with Patients: Designing, Participating in and Reporting Health Ou...
 
Workshop 4 - "EURORDIS Research Policy recommendation"
Workshop 4 - "EURORDIS Research Policy recommendation"Workshop 4 - "EURORDIS Research Policy recommendation"
Workshop 4 - "EURORDIS Research Policy recommendation"
 
EUPATI’s framework on Informing the “health-interested” public about medicine...
EUPATI’s framework on Informing the “health-interested” public about medicine...EUPATI’s framework on Informing the “health-interested” public about medicine...
EUPATI’s framework on Informing the “health-interested” public about medicine...
 
2010 11 13 european cme forum jan geissler 1.5
2010 11 13 european cme forum jan geissler 1.52010 11 13 european cme forum jan geissler 1.5
2010 11 13 european cme forum jan geissler 1.5
 
The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...
 
Time matters-brochure-digital
Time matters-brochure-digitalTime matters-brochure-digital
Time matters-brochure-digital
 
Introduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI updateIntroduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI update
 
Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...
 
ENCA 2016 - Genoa - Bas Vastert
ENCA 2016 - Genoa - Bas VastertENCA 2016 - Genoa - Bas Vastert
ENCA 2016 - Genoa - Bas Vastert
 
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
 
European Union Action in the field of Rare Diseases
European Union Action in the field of Rare DiseasesEuropean Union Action in the field of Rare Diseases
European Union Action in the field of Rare Diseases
 
Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015 Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015
 
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
 

Plus de EURORDIS - Rare Diseases Europe

RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...EURORDIS - Rare Diseases Europe
 
RareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare diseaseRareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare diseaseEURORDIS - Rare Diseases Europe
 
Update on the Mysasthenia Gravis community on RareConnect.org
Update on the Mysasthenia Gravis community on RareConnect.orgUpdate on the Mysasthenia Gravis community on RareConnect.org
Update on the Mysasthenia Gravis community on RareConnect.orgEURORDIS - Rare Diseases Europe
 
RareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients GloballyRareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients GloballyEURORDIS - Rare Diseases Europe
 
Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...EURORDIS - Rare Diseases Europe
 
Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...EURORDIS - Rare Diseases Europe
 
Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...EURORDIS - Rare Diseases Europe
 
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe" Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe" EURORDIS - Rare Diseases Europe
 
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"EURORDIS - Rare Diseases Europe
 
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"EURORDIS - Rare Diseases Europe
 
Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...EURORDIS - Rare Diseases Europe
 
Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"EURORDIS - Rare Diseases Europe
 

Plus de EURORDIS - Rare Diseases Europe (20)

RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...
 
RareConnect.org Update 2016
RareConnect.org Update 2016RareConnect.org Update 2016
RareConnect.org Update 2016
 
RareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare diseaseRareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare disease
 
Living with TRAPS poll results
Living with TRAPS poll resultsLiving with TRAPS poll results
Living with TRAPS poll results
 
Pitt Hopkins syndrome community on RareConnect.org
Pitt Hopkins syndrome community on RareConnect.orgPitt Hopkins syndrome community on RareConnect.org
Pitt Hopkins syndrome community on RareConnect.org
 
The Value of Online Communities
The Value of Online CommunitiesThe Value of Online Communities
The Value of Online Communities
 
Updates to RareConnect.org in 2014
Updates to RareConnect.org in 2014Updates to RareConnect.org in 2014
Updates to RareConnect.org in 2014
 
Update on the Mysasthenia Gravis community on RareConnect.org
Update on the Mysasthenia Gravis community on RareConnect.orgUpdate on the Mysasthenia Gravis community on RareConnect.org
Update on the Mysasthenia Gravis community on RareConnect.org
 
Surveys and polls: The RareConnect.org Experience
Surveys and polls: The RareConnect.org ExperienceSurveys and polls: The RareConnect.org Experience
Surveys and polls: The RareConnect.org Experience
 
RareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients GloballyRareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients Globally
 
Rare disease day 2011 highlights
Rare disease day 2011 highlightsRare disease day 2011 highlights
Rare disease day 2011 highlights
 
Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...
 
Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...
 
Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...
 
Conference 3 "Outcomes of 15 National Conferences, "
Conference 3   "Outcomes of 15 National Conferences, "Conference 3   "Outcomes of 15 National Conferences, "
Conference 3 "Outcomes of 15 National Conferences, "
 
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe" Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
 
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
 
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
 
Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...
 
Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"
 

Session 2 graf_von_der_schulenburg

  • 1. The German Plan for Rare Diseases: A Development in Progress J.-Matthias Graf von der Schulenburg Krakow, 14 May 2010
  • 2.
  • 3.
  • 4. Why do we need health service research ? Dimensions of an economic evaluation… © Prof. Dr. J.-M. Graf von der Schulenburg Allocation Efficiency Stabilization Cost stability and continuity of the system Distribution Fair allocation Facts Appraisements
  • 5.
  • 6.
  • 7.
  • 8. Which perspectives were taken into account? © Prof. Dr. J.-M. Graf von der Schulenburg Patient organizations (people concerned) Evaluation of experiences Health care provider (physicians, industry) Evaluation of markets and science Public organizations/ benefactors Evaluation of structures
  • 9. Rare Diseases are currently attracting insufficient attention in Germany © Prof. Dr. J.-M. Graf von der Schulenburg Quelle : BMG-study 2009
  • 10. Which individual care factors are important for patients? © Prof. Dr. J.-M. Graf von der Schulenburg Source: BMG-study 2009 High competence of medical care Information about new treatment possibilities Psychosocial care … Fast access to new drugs Europe-wide treatment options Close to residential care
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Thank you for your attention!

Notes de l'éditeur

  1. Generell soll das Aktionsbündnis Beiträge zur Umsetzung der Ratsempfehlung liefern. Dabei stehen Beiträge zur Erstellung und zum Monitoring eines Nationalen Aktionsplans für Seltene Erkrankungen sowie zur Umsetzung der Forderung nach nationalen Referenzzentren im Vordergrund. Weiterhin soll durch Bündelung der bisherigen Initiativen einzelner Akteure die Transparenz erhöht, Doppelarbeiten vermieden und die Wirkung dieser Initiativen verbessert werden. Es sollen auch neue Maßnahmen (z. B. Modellprojekte) zur Verbesserung der gesundheitlichen Situation von Menschen mit Seltenen Erkrankungen zwischen Bund, Ländern und den weiteren Akteuren des Gesundheitswesens koordiniert werden. Die Förderung dieser weiterführenden Aktionen erfolgt durch die Akteure des NAMSE. Hier wären auch Public-Private Partnerships denkbar. Säulen: ACHSE, BMBF, BMG
  2. Die Steuerungsgruppe ist das maßgebliche Entscheidungsgremium des Kooperationsverbundes und für den Nationalen Aktionsplan Seltene Erkrankungen. Sie setzt sich zusammen aus Vertretern der wesentlichen Akteuren aller relevanter Bereiche. Die Steuerungsgruppe legt die grundsätzlichen Ziele fest, die in den Arbeitsgruppen bearbeitet werden. Sie verabschiedet Handlungs- und Umsetzungsempfehlungen für den Nationalen Aktionsplan Seltene Erkrankungen. Die Sitzungen der Steuerungsgruppe werden vom BMG geleitet Steuerungsgruppe setzt sich aus Bündnispartnern zusammen.
  3. Die Arbeitsgruppen leisten die fachlich-inhaltlichen Ausarbeitungen zu den Themen. Die Mitglieder der Arbeitsgruppen werden von der Steuerungsgruppe benannt. Die Sitzungen der Arbeitsgruppen werden geleitet von einem Sprecher, der von den Arbeitsgruppenmitgliedern gewählt wird. Je nach Bedarf werden externe Experten hinzugeladen. Jede Arbeitsgruppe wird durch die zuständigen Fachreferate des BMG und BMBF "betreut". Zur Sicherung der Arbeitsfähigkeit der AG soll eine bestimmte Anzahl von Mitgliedern nicht überschritten werden. Vorgeschlagen werden maximal 12 Teilnehmer je Arbeitsgruppe. Bei speziellen Fragestellungen können ggf. gezielt weitere Experten temporär in die AG eingebunden und Unterarbeitsgruppen eingerichtet werden. Die Mitglieder der AG können personenidentisch zur Mitgliedschaft der Steuerungsgruppe sein. Diese Entscheidung obliegt den vertretenen Akteuren. Die Benennung der AG-Mitglieder erfolgt durch die Steuerungsgruppe.
  4. Unterstützt wird das NAMSE durch eine externe Geschäftsstelle. Diese unterstützt die Steuerungsgruppe des Bündnisses und gewährleistet die Funktionsfähigkeit der Gremien. Geführt wird die Geschäftsstelle von einem Leiter/einer Leiterin und hat folgende Aufgaben: Koordinierung der Arbeit des Aktionsbündnisses, d.h. primärer Ansprechpartner für Steuerungsgruppe und Arbeitsgruppen wie auch BMG, BMBF und Selbsthilfe (Kommunikationszentrale), wissenschaftlich-fachliche und administrativ-organisatorische Unterstützung des Aktionsbündnisses (Steuerungsgruppe, Arbeitsgruppen und BMG, BMBF und Selbsthilfe), Einberufung der Sitzungen Steuerungsgruppe sowie der Arbeitsgruppen, Presse- und Öffentlichkeitsarbeit in Abstimmung mit der Steuerungsgruppe, Vorbereitung von (Modell-)Projekten und weiteren Aktionen.
  5. s. Botschaften